3rd booster shot of Covaxin shows positive responses

The booster shot was given six months after the second Covaxin dose.

Medicine Injection drug vaccine Syringe
Picture: Pixabay

Last Updated on January 11, 2022 by The Health Master

A third booster shot of Covaxin administered six months after the second dose has shown good immune memory responses and long-term protection from severe disease, a study by Bharat Biotech and Pune-based National Institute of Virology (NIV) has found.

The study, titled-Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomized controlled trial’, found that 90% of the recipients of the booster dose had a “detectable neutralizing antibody response” against the wild-type strain six months after the second C-19 dose.

It found that the reactogenicity (adverse reactions in the patient) after receiving the vaccine or placebo was minimal and comparable, and no serious adverse events were reported, it found. The booster shot was given six months after the second Covaxin dose.

According to researchers, cell-mediated immunity and neutralizing antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta and Delta plus) persisted above the baseline but the magnitude of responses declined.

However, after a third jab, the neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19- to 97-fold, indicating that a booster dose may be required to prevent breakthrough infections, the paper said.

“Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections,” said the study.

“These trial results provide a strong foundation toward our goal of providing Covaxin as a booster dose. Our goal of developing a global vaccine against C-19 has been achieved.

Covaxin is now indicated for adults, children, 2 dose primary and booster doses. This enables the use of Covaxin as an universal vaccine,” Krishna Ella, Chairman and Managing Director of Bharat Biotech, said in a statement.

The study has appeared in the preprint of medRxiv and is yet to be peer reviewed. The study was conducted during the second C-19 wave.



Sputnik V


FDA asks Chemists and Hospitals to ramp up medicine supply

India to become hub for Covid-19 antiviral medicines

15 New Drugs to be developed: Sanofi

DTAB agrees to amend Rules for OTC drugs and license displaying…

IPC releases 9th amendment list of 40 monographs to IP 2018

USFDA gives nod to Alembic Pharma for Vortioxetine tablets

Covid: Govt warns against self-medication, steroid use

Molnupiravir has serious safety concerns: ICMR

USFDA gives nod to Alembic for generic drug to treat Parkinson’s…

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner